A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
Active, not recruiting · NCT05773092 · Registry updated 2026-06-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC | non-small cell lung carcinoma | Active, not recruiting | Phase 2 | 2026-06-22 | NCT05773092 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Centre, Singapore | 44 |
| Taiho Pharmaceutical Co., Ltd. | 8 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Cancer Center Singapore | Singapore | Singapore | 3 |